- Home
- KZIA
as 02-21-2025 12:39pm EST
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | NEW SOUTH WALES 2113 |
| Market Cap: | 6.0M | IPO Year: | 1999 |
| Target Price: | $11.50 | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $15.80 | Next Earning Date: | 03-26-2025 |
| Revenue: | $1,655,324 | Revenue Growth: | 248000.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kazia Therapeutics Limited News
KZIA Breaking Stock News: Dive into KZIA Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
Insider Monkey
21 days ago
Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?
MT Newswires
22 days ago
Sector Update: Health Care Stocks Gain Thursday
MT Newswires
22 days ago
Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced
PR Newswire
22 days ago
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
Insider Monkey
25 days ago
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?
PR Newswire
a month ago
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
TipRanks
a month ago
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
Compare KZIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZIA Kazia Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.